FFA
BMRN icon

Fi3 Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fi3 Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,573
Closed -$202K – 236
2026
Q1 		$202K Buy
+3,573
New +$208K 0.06% 214

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fi3 Financial Advisors's BMRN Position: Q2 2026 in Review

Fi3 Financial Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 3,573 shares — an estimated $202K sold.

Fi3 Financial Advisors first reported a position in BMRN in Q1 2026 and held it in 1 quarter. The position peaked at $202K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Fi3 Financial Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fi3 Financial Advisors sold 3,573 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $202K.
  • Fi3 Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Fi3 Financial Advisors's BioMarin Pharmaceuticals position peaked at $202K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Fi3 Financial Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.